More than 350 drugs will increase in price, including Pfizer, GSK, BMS, AZ and Sanofi

More drug prices are likely to be announced in January – the largest price
hike for drugmakers in history.

Recently, according to Reuters, according to healthcare research company 3 Axis Advisors According to the data analyzed, multinational big pharmaceutical companies including Pfizer, GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca and Sanofi plan to raise 350 in the United States in early January 2023 The price of
a variety of unique drugs.

These increases are expected to come as the pharmaceutical industry prepares for the Biden administration's Inflation Reduction Act (IRA), which allows the government's Medicare health plan to be established from 2026 Began direct negotiations on the price of
certain drugs.
The industry is also battling inflation and supply chains, leading to constraints
on higher manufacturing costs.
The increased price does not include rebates and other discounts
to pharmacy benefit managers.

According to data released by 46brooklyn, a drug pricing nonprofit associated with 3 Axis, drugmakers raised the price
of more than 1,400 drugs in 2022.
This is since 2015 The biggest increase since then
.
According to 46Brooklyn, the median drug price increase last year was 4.
9 percent, compared to an average increase of 6.
4 percent
.
Both figures are lower than the inflation rate
in the United States.

Drugmakers essentially keep price increases at 10% or below – an industry practice followed by many large drugmakers as they came under fire
for raising prices too much in the middle of the past decade.

3 Antonio Ciaccia, President of Axis Drugmakers have focused on launching their drugs
at higher prices because of concerns about annual price increases.
"Drugmakers have to take a closer look at calibrating these launch prices from the start.
.
.
So that they don't trap themselves at a point where they won't be able to return to profitability through price increases in the future," he said
.

More drug prices are likely to be announced in January – the largest price
hike for drugmakers in history.

Pfizer has announced the largest price increase to date, with prices rising for 89 unique drug brands, as have 10 drug brands in its Hospira division
.
Pfizer's price increases include: The cost of Xeljanz, a drug that treats autoimmune diseases, including rheumatoid arthritis and ulcerative colitis, and the anti-cancer drugs Ibrance and Xalkori, rose by 6%.
The price of prices rose by 7.
9%.

A Pfizer spokesperson said in an email that the company's average list price for drugs and vaccines in 2023 was well below about 3.
6 percent the general inflation rate, and noted the need to raise prices to support investment in
drug discovery.
Pfizer noted that net prices — the prices of drugs the company actually receives — have declined
over the past four years as a result of higher rebates and discounts paid to insurers and pharmacy benefit managers.

It is followed by GlaxoSmithKline, which so far plans to increase the price of 26 unique drugs, including the price increase of its popular shingles vaccine, Shingrix 7%
。 GlaxoSmithKline was not immediately available for comment
.

Significant gains expected include a 9% increase in Bristol-Myers Squibb's personalized CAR-T cell therapies Abecma and Breyanzi, both of which have been exceeded in blood cancer treatment prices $
400,000.
A company spokesperson said there were several drivers of the list price increase for both CAR-T cell therapies, including inflation, the value of the therapy, and CAR-T The individual nature
of the manufacturing process.

AstraZeneca is preparing to raise the price of the blood cancer treatment Calquence, the non-small cell lung cancer drug Tagrisso and the asthma treatment drug Fasenra 3%
。 "AstraZeneca has always taken a thoughtful approach to pricing, and we will continue to do so, taking into account many factors," said Brendan McEvoy, a company spokesman
.

McEvoy said that in addition to significant R&D investments, AstraZeneca considers clinical value, patient size size, government/payer coverage requirements, patient affordability, competition and other market conditions
.

Sanofi plans to raise the price of
its 14 drugs or vaccines.
A Sanofi spokesperson said the drugmaker 2023 years' pricing actions are in line with its responsible pricing approach, compliance with government policies, and the need
to respond to changing market trends.